Replies to post #10832 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Vin,

My Apoligies, it was 10nis who made the same false statement as you did and I corrected him on it on july 30th. And by the way your incorrect statement isn't irrelevant.

There's no question that Momenta would be earning more revenue if it's percentages were higher, that's common sense to anyone. But the point is it would be nowhere in the area you suggested. Your quote was If MNTA had the Copaxone type deal for mENOX, they would be getting $80-$100 million/quarter despite Amphastar's entry.

Now if you made a misspell and meant $80/$100 mil per Year I undersand, but that isn't what you said. Maybe you could consider a retrack of the liar crap.